Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral sclerosis (ALS). The trial is expected to enroll 210 ALS patients. Each will receive one of two usnoflast…
News
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on a Phase 1 clinical trial that’s testing AMX0114, Amylyx Pharmaceuticals’ investigational treatment for amyotrophic lateral sclerosis (ALS). The hold came in November after Amylyx asked to initiate the first-in-human studies for AMX0114 at a starting…
The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together researchers, healthcare professionals, advocates, patients, and caregivers in a quest to make amyotrophic lateral sclerosis (ALS) a more livable disease. The ALS Nexus 2025 event will take place Aug.
Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS) who received the treatment in a real-world setting, according to a study involving seven patients carrying mutations in the SOD1 gene. Data also showed robust and sustained declines in markers of…
A diet containing foods that quickly raise blood sugar is associated with slower amyotrophic lateral sclerosis (ALS) progression in people taking the standard treatment riluzole, according to data from a recent study. Scientists had previously found that a high glycemic index (GI) and glycemic load (GL) — two measures…
Constipation, a symptom experienced by about half of amyotrophic lateral sclerosis (ALS) patients, is associated with a significantly faster disease progression and poorer survival, according to a new study. Constipation was also linked to worse anxiety, depression, and sleep problems, data showed. “Objective assessment of these symptoms is critical…
Living next to arable cropland significantly raises the risk of developing amyotrophic lateral sclerosis (ALS), according to a new study in northwestern Italy. A significantly younger age at disease onset also was seen among those living near such farmland, which may include fields of cereals (wheat and barley), beans,…
Note: This story was updated July 24, 2025, to correct the name of Nova Southeastern University. A Chicago businessman and philanthropist — David Husman, founder and chairman of Heartland Real Estate Partners — has donated $20 million to advance research into amyotrophic lateral sclerosis (ALS) and patient care at…
Alchemab Therapeutics has partnered with Eli Lilly to develop new antibody treatments for amyotrophic lateral sclerosis (ALS) based on an approach that looks at the immune response of those with slower disease progression. Alchemab will identify, develop, and market up to five new antibody-based candidates. The company…
Team Gleason has expanded its collaboration with Synchron to raise awareness about the company’s BCI Community, an initiative that’s designed to help people with disabilities and their loved ones know more about brain-computer interface (BCI) solutions and gather insights to advance their development. BCIs can detect activity in…
Recent Posts
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’
- Higher blood lactate levels tied to survival, weight changes in ALS
- AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial